A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
| Errataetall: |
CommentOn: Intern Med. 2021 Feb 1;60(3):423-429. - PMID 32963156 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 60(2021), 3 vom: 01. Feb., Seite 325-326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Siqi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2021 Date Revised 12.03.2021 published: Print-Electronic CommentOn: Intern Med. 2021 Feb 1;60(3):423-429. - PMID 32963156 Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.5962-20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315343508 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315343508 | ||
| 003 | DE-627 | ||
| 005 | 20231225154718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.5962-20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315343508 | ||
| 035 | |a (NLM)32963172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Siqi |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2021 | ||
| 500 | |a Date Revised 12.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Intern Med. 2021 Feb 1;60(3):423-429. - PMID 32963156 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a cytokine | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a immune-related adverse event | |
| 650 | 4 | |a myocarditis | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Tajiri, Kazuko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 60(2021), 3 vom: 01. Feb., Seite 325-326 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:3 |g day:01 |g month:02 |g pages:325-326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.5962-20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 3 |b 01 |c 02 |h 325-326 | ||